Association of KIR genes and HLA-C alleles with HPV-related uterine cervical disease in Korean women

Tissue Antigens

Volumn 81, Issue 3, 2013, Pages 164-170

  Song, M J ^a   Lee, C W ^a   Kim, J H ^a   Lee, S J ^a   Kim, C J ^a   Hur, S Y ^a   Park, T C ^a   Kim, T G ^a   Park, J S ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Human leukocyte antigen C alleles; Human leukocyte antigens; Human papillomavirus infection; Killer cell immunoglobulin like receptors; KIR genes; Natural killer cells; Uterine cervical disease

Indexed keywords

HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INFECTION SENSITIVITY; KOILOCYTOTIC ATYPIA; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX DISEASE;

ADULT; AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HLA-C ANTIGENS; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; RECEPTORS, KIR; REPUBLIC OF KOREA; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84873606779     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12068     Document Type: Article

References (38)

1. Zur HH. Papillomavirus infections: a major cause of human cancers. Biochim Biophys Acta 1996: 1288: 55-78.
2. Das BC, Hussain S, Nasare V, Bharadwaj M. Prospects and prejudices of human papillomavirus vaccines in India. Vaccine 2008: 26: 2669-79.
3. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008: 168: 123-37.
4. Jones J, Saleem A, Rai N et al. Human Papillomavirus genotype testing combined with cytology as a 'test of cure' post treatment: the importance of a persistent viral infection. J Clin Virol 2011: 52: 88-92.
5. Piras F, Piga M, De Montis A et al. Prevalence of human papillomavirus infection in women in Benin, West Africa. Virol J 2011: 8: 514.
6. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011: 103: 368-83.
7. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010: 117: S5-10.
8. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009: 101: 1120-30.
9. Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L. What is a natural killer cell? Nat Immunol 2002: 3: 6-8.
10. Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 2001: 19: 291-330.
11. Lanier LL. On guard-activating NK cell receptors. Nat Immunol 2001: 2: 23-7.
12. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002: 20: 217-51.
13. Khakoo SI, Thio CL, Martin MP et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004: 305: 872-4.
14. Bonagura VR, Du Z, Ashouri E et al. Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis. Hum Immunol 2010: 71: 212-9.
15. Martin MP, Gao X, Lee JH et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002: 31: 429-34.
16. Carrington M, Wang S, Martin MP et al. Hierarchy of resistance to cervical neoplasia related by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med 2005: 201: 1069-75.
17. Arnheim L, Dillner J, Sanjeevi CB. A population-based cohort study of KIR genes and genotypes in relation to cervical intraepithelial neoplasia. Tissue Antigens 2005: 65: 252-9.
18. Paul WE. Fundamental Immunology, 4th edn. Philadelphia: Lippincott-Raven, 1999, 1131.
19. Wang SS, Hildesheim A, Gao X et al. Comprehensive analysis of human leukocyte antigen class I alleles and cervical neoplasia in 3 epidemiologic studies. J Infect Dis 2002: 186: 598-605.
20. Wang SS, Hildesheim A, Gao X et al. Human leukocyte antigen class I alleles and cervical neoplasia: no heterozygote advantage. Cancer Epidemiol Biomarkers Prev 2002: 11: 419-20.
21. Wang SS, Wheeler CM, Hildesheim A et al. Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J Infect Dis 2001: 184: 1310-4.
22. Neuman RJ, Huettner PC, Li L et al. Association between DQB1 and cervical cancer in patients with human papillomavirus and family controls. Obstet Gynecol 2000: 95: 134-40.
23. Liang J, Xu A, Xie Y, Awonuga AO, Lin Z. Some but not all of HLA-II alleles are associated with cervical cancer in Chinese women. Cancer Genet Cytogenet 2008: 187: 95-100.
24. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat Genet 1994: 6: 157-62.
25. Odunsi K, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS. Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. Int J Cancer 1996: 67: 595-602.
26. Hildesheim A, Schiffman M, Scott DR et al. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States. Cancer Epidemiol Biomarkers Prev 1998: 7: 1035-41.
27. Gregoire L, Lawrence WD, Kukuruga D, Eisenbrey AB, Lancaster WD. Association between HLA-DQB1 alleles and risk for cervical cancer in African-American women. Int J Cancer 1994: 57: 504-7.
28. Wank R, Thomssen C. High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature 1991: 352: 723-5.
29. Wank R, Meulen JT, Luande J, Eberhardt HC, Pawlita M. Cervical intraepithelial neoplasia, cervical carcinoma, and risk for patients with HLADQB1*0602,*301,*0303 alleles. Lancet 1993: 341: 1215.
30. Bernard HU. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 2005: 32: S1-6.
31. Schiffman M, Rodriguez AC, Chen Z et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res 2010: 70: 3159-69.
32. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006: 6: 753-63.
33. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 2000: 191: 961-76.
34. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997: 18: 89-95.
35. Garcia-Iglesias T, Del Toro-Arreola A, Albarran-Somoza B et al. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 2009: 9: 186.
36. Textor S, Dürst M, Jansen L et al. Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer 2008: 123: 2343-53.
37. Nakagawa M, Stites DP, Farhat S et al. T-cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia. Clin Diagn Lab Immunol 1996: 3: 205-10.
38. Nakagawa M, Stites DP, Farhat S et al. Cytotoxic T lymphocyte response to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis 1997: 175: 927-31.